Cantabio Pharmaceuticals Inc. has been awarded a grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of a cell-penetrant DJ-1 protein replacement therapeutic candidate for the treatment of Parkinson’s disease.
An international working group has proposed a new research framework that stages Parkinson's disease (PD) and defines it based on the disease's underlying biology, rather than on clinical symptoms.
Vesper Bio ApS has been awarded a grant worth $873,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to assess sortilin inhibition in Parkinson’s disease.
Nysnobio Inc. has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to assist the advancement of the company’s lead parkin gene replacement therapy candidate, NB-001. The funding will support product manufacturing to enable IND safety studies in preparation for clinical trials evaluating NB-001 in Parkinson’s disease patients with biallelic loss-of-function mutations in the parkin gene, or parkin-PD.
Evidence of mitochondrial and lysosome dysfunction underlying Parkinson’s disease (PD) was discussed during several talks at the World Parkinson Congress 2023 (WPC) held in Barcelona. Edward A. Fon, from McGill University in Montreal, explained how eyes turned to mitochondria as key players in PD more than 30 years ago and how the explosion of genetics was fundamental to advance the knowledge and research in PD.
Olatec Therapeutics LLC has been awarded a research grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to evaluate its lead molecule, dapansutrile (OLT-1177), in preclinical Parkinson’s disease progression models.
NRG Therapeutics Ltd. has been awarded a second US$500,000 grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF), to support its lead drug discovery program and the development of a novel treatment for Parkinson's disease.
